Vertex filed a biologics license application after late‑stage Rainier data showed substantial reduction in proteinuria for immunoglobulin A nephropathy (IgAN). The company reported a marked drop in urine protein-to-creatinine ratio versus placebo in the Phase III population and plans a regulatory push toward accelerated approval. Vertex acquired the candidate via a $4.9 billion deal and positions the drug as potential best‑in‑class amid competition from Otsuka and Vera. Analysts flagged the magnitude of the proteinuria response as differentiating; investors see rapid regulatory timelines possible given the unmet need. Vertex is preparing submission packages and regulatory interactions; if cleared, the agent could reshape the IgAN treatment market and command significant sales given disease prevalence and limited current options.